A Potential Drug For Liver Carcinoma

Main Category: Liver Disease / Hepatitis
Also Included In: Biology / Biochemistry;  Cancer / Oncology
Article Date: 25 May 2009 - 2:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:4 and a half stars

4.33 (3 votes)

Healthcare Prof:3 and a half stars

3.5 (2 votes)


Looking for efficient anti-tumor drugs is a hot research area. Chrysin (5,7-dihydroxy flavone), a natural widely-distributed flavonoid, has been reported to have many different biological activities such as anti-oxidant, anti-virus, antidiabetogenic activity and clear anxiolytic effect. However, Chrysin is limited in its clinical application because of its modest absorption in the intestine and rapid in vivo glycosylation. To improve the biological activity of chrysin, a number of its derivatives have been prepared for biological testing. 5-allyl-7-gen-difluoromethylenechrysin (ADFMChR) is one of them.

A research team led by Dr. Jian-Guo Cao from China investigate the anti-tumor effect of ADFMChR in vitro. Their study was published on May 14, 2009 in the World Journal of Gastroenterology.

In their study, HepG2 cells and L-02 cells were cultured and the inhibitory effect of ADFMChR on their proliferation was measured by MTT assay. The apoptosis of HepG2 cells was determined by flow cytometry using propidium iodide fluorescence staining. The influence of ADFMChR on the proxisome proliferator-activated receptor γ (PPARγ), NF-κB, Bcl-2 and Bax protein expression of HepG2 cells were analyzed by Western blotting.

They found that ADFMChR significantly inhibited the proliferation of HepG2 cells in a dose-dependent manner, with little effect on growth of L-02 cells. Western blotting analysis revealed that after 24 h of treatment with 3.0, 10.0, 30.0 μmol/L ADFMChR, PPARγ and Bax protein expression increased but Bcl-2 and NF-κB expression decreased in HepG2 cells; however, pre-incubation with 10.0 μmol/L GW9662, a blocker of PPARγ, could efficiently antagonize and weaken the regulatory effect of 3.0, 30.0 μmol/L ADFMChR on PPARγ and NF-κB protein expression in HepG2 cells.

This finding may provide a molecular basis for the clinically observed cancer-preventive effects of ADFMChR and new clues for research about pharmaceutical prevention and cure of human liver carcinoma.

Reference: Tan XW, Xia H, Xu JH, Cao JG. Induction of apoptosis in human liver carcinoma HepG2 cell line by 5-allyl-7-gendifluoromethylenechrysin. World J Gastroenterol 2009; 15(18): 2234-2239 http://www.wjgnet.com/1007-9327/15/2234.asp

Correspondence to: Dr. Jian-Guo Cao, Laboratory of Medicine Engineering, Medical College, Hunan Normal University, Changsha 410006, Hunan Province, China.

Source:
Lai-Fu Li
World Journal of Gastroenterology

Article adapted by Medical News Today from original press release.
Visit our liver disease / hepatitis section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Lai-Fu Li. "A Potential Drug For Liver Carcinoma." Medical News Today. MediLexicon, Intl., 25 May. 2009. Web.
14 Feb. 2012. <http://www.medicalnewstoday.com/releases/151241.php>

APA
Lai-Fu Li. (2009, May 25). "A Potential Drug For Liver Carcinoma." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/151241.php.

Please note: If no author information is provided, the source is cited instead.


Liver Disease / Hepatitis

Most Popular Articles



Follow Our Liver Disease News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Liver Disease / Hepatitis Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »